alpha-aminopyridine has been researched along with hh-gv678 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, LJ; Ge, F; Han, BH; Lu, RZ; Ma, J; Qiu, L; Wang, XD; Wang, XL; Yu, BH; Zhan, ZM; Zhang, BL | 1 |
| Chen, X; Deng, P; Gong, A; Zhong, D | 1 |
| Fu, L; Lou, L; Luo, H; Quan, H; Xie, C; Xu, Y | 1 |
| Chen, X; Liu, K; Yang, Y; Zhong, D | 1 |
| Jin, L; Kong, X; Lou, L; Quan, H; Xu, Y; Zhao, J | 1 |
| Chang, MX; Ma, YP | 1 |
| Guo, C; He, QN; Huang, J; Kuang, Y; Pei, Q; Song, HL; Wu, ST; Yang, GP; Yang, S; Yang, XY; Ye, L | 1 |
| Chen, J; Chen, L; Guo, S; Lei, J; Xu, P; Xu, T; Yu, L; Yu, X; Zhou, X; Zhu, S | 1 |
| Cui, J; Gu, J; Hu, Y; Jiang, H; Jiang, M; Jin, J; Li, J; Li, Y; Liu, B; Liu, L; Liu, X; Luo, J; Meng, L; Ouyang, G; Qiao, J; Sun, A; Wang, J; Xie, X; Yang, T; Zhang, L; Zhang, M; Zhang, W; Zhang, X; Zhang, Y; Zhao, C; Zhu, H | 1 |
| Müller, MC | 1 |
| Chen, L; Liu, J; Mi, RH; Wei, XD; Wei, XL; Yang, HP; Yin, QS; Zhang, LN | 1 |
1 trial(s) available for alpha-aminopyridine and hh-gv678
| Article | Year |
|---|---|
Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects.
Topics: Adolescent; Adult; Aminopyridines; Asian People; Benzamides; Cross-Over Studies; Diet, High-Fat; Female; Follow-Up Studies; Food-Drug Interactions; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Tissue Distribution; Young Adult | 2020 |
10 other study(ies) available for alpha-aminopyridine and hh-gv678
| Article | Year |
|---|---|
[Effect of a novel tyrosine kinase inhibitor HHGV678 on growth inhibition of Bcr-Abl wild type and IM-resistant cell lines in vitro].
Topics: Aminopyridines; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients.
Topics: Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Agents; Benzamides; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Structure; Protein Kinase Inhibitors; Young Adult | 2010 |
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Simultaneous determination of flumatinib and its two major metabolites in plasma of chronic myelogenous leukemia patients by liquid chromatography-tandem mass spectrometry.
Topics: Aminopyridines; Antineoplastic Agents; Benzamides; Chromatography, Liquid; Drug Stability; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Indoles; Interleukin-3; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Random Allocation; Sunitinib | 2014 |
[Effect of flumatinib mesylate on C-MYC, HIF-1α and VEGF in U226 line].
Topics: Aminopyridines; Benzamides; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Genes, myc; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Vascular Endothelial Growth Factor A | 2013 |
Metabolic interactions between flumatinib and the CYP3A4 inhibitors erythromycin, cyclosporine, and voriconazole.
Topics: Aminopyridines; Animals; Benzamides; Cyclosporine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Female; Humans; Male; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Voriconazole | 2020 |
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.
Topics: Aminopyridines; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmaceutical Preparations; Piperazines; Pyrimidines; Treatment Outcome | 2021 |
New Drug for Chronic Myeloid Leukemia Might Stimulate the Market.
Topics: Aminopyridines; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2021 |
[Clinical efficacy and safety of flumatinib combined with multidrug chemotherapy in the treatment of 12 cases with Ph(+) acute lymphoblastic leukemia].
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2021 |